Member Info for Updg02

I am LTH, but not totally convinced by today's statement. There are many positives, aside from the profit warning. Yes, we may now get further offers for the 3 non core businesses as the flag has been raised. The company is very upbeat in these areas and hence, a better price may now be forthcoming. The tone is very similar to 6 months ago, with a very upbeat outlook but jam tomorrow. I appreciate much of this is outside of the companies control. There is undoubtably huge potential given all the world uncertainty, but how long is this going to take to turn it into profit. I fear we may seem some selling at the bell.

Several prints have just gone through for just under 14 million shares hence, the negative price action today.

I keep thinking why the share keeps on falling. I get the bit about he naked shorts (which the company are trying to address) but what else could be driving this; is it the technology, isn't it as good as we are led to believe? Will it be difficult to monitise the technology or something. I keep topping up, but do wonder whether I am just throwing good money after bad!!

Very frustrating. How low can this go? Thought the board would be filling their boots at these levels. I think this will tread water at best until a new contract comes in from the UK or middle east. Keep holding the faith.

There may well be a lot of potential business out there who haven't committed due to the ongoing finance woes of the company. Hopefully, this will be resolved and we will move forward at a pace.

I share everyone 's frustration here but most regulatory bodies aren't interested in us PI's and are pretty toothless anyway. In my opinion, patience is required here and we need to wait until the next positive news update. This will send the SP north very quickly. Best not to get too worried about short term movements unless you were looking for a quick trade. We are all well underwater but I believe our day will come in the next 12-18 months. Good luck to all.

186k shares traded during normal hours accompanied by a small rise in the SP. After hours, a further 730k shares traded and we are forecast to be up 30% pre market. Not complaining, but it's hard to get a handle of what's happening here!

The following release has just been issued. The positive is that things are moving forwards, but not sure this will do anything for the price in the short term. A year plus wait to confirm what will be hopefully very positive results.

DALLAS, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASD:MDAI)

(“Spectral AI” or the “Company”), an artificial intelligence (AI)

company focused on medical diagnostics for faster and more accurate treatment

decisions in clinical wound care, announces the enrollment of the first

patient in the pivotal study to validate DeepView AI(®) using its

proprietary imaging technology for burn size and healing assessment. This

pivotal study is expected to be the final clinical trial before seeking FDA

marketing authorization for the burn indication in 2025 and will be conducted

in burn centers and emergency departments across the US, enrolling both adults

and pediatric patients.

Niko Pagoulatos, Ph.D., Chief Operating Officer of the Company stated: “We

believe this study will further demonstrate the truly innovative and versatile

nature of our technology, as well as its ability to predict burn wound healing

potential on the first day of injury with significantly greater accuracy and

speed than the methods currently used today. We continue to utilize $251

million of non-dilutive government funding since 2019 to validate DeepView for

burn indication, while aggressively advancing other clinical indications like

diabetic foot ulcers in pursuit of our ‘one platform—multiple clinical

indications’ strategy.”

“We are excited to begin enrollment in this pivotal study implementing the

DeepView system in clinical sites across the United States. The study will

help us validate DeepView’s game-changing AI to accurately assess burn wound

healing potential on day-one which could lead to early treatment decisions,”

said Jeffrey C. Carter, MD, FACS, the lead investigator for the study. “This

study is anticipated to deepen the knowledge and understanding of how DeepView

will transform burn care pathways while improving patient outcomes,

concurrently strengthening our country against the challenges of Burn Mass

Casualty Incidents to safeguard and prepare for unforeseen emergencies.”

The data obtained in the study will be compared to assessment by physicians

and used for regulatory submission to the FDA by the first half of 2025.

I am a LTH, but this seems more like a cash raising exercise to avoid dilution and the directors lending more money to the business. We need to widen our sales beyond SLB. My view is we will continue to trend sideways until more contracts with new partners are won.

Interesting article published in the IC today following a meeting in congress. It involves Diversified Energy and their performance on preventing methane leaks on some of their old and abandoned wells. Hopefully, our sales team are all over this.

Members of the US Congress have called for Diversified Energy (DEC) to outline how it is stopping methane leaks from its tens of thousands of mature gas wells.

Four Democratic members of the House Committee on Energy and Commerce wrote to Diversified boss Rusty Hutson Jr on Monday.

“As the largest owner and purchaser of oil and gas wells in the United States, Diversified Energy is responsible for remediating a substantial share of the country’s ageing oil and gas wells, but we are concerned that your company may be vastly underestimating well cleanup costs,” wrote the members.

The company was built on buying up older wells for cheap and running them until dry. Various reports have alleged a lax approach to plugging leaking wells given the sheer scale of Diversified’s portfolio, including a Bloomberg investigation in 2021 that the House committee quotes from extensively.

I am a bit more positive given the outlook and interest from other 3rd parties. Assuming a full year EPS of around 80p leaves us currently currently on a p/e of around 11. The feels way too low given the outlook. We also have the potential of a sale further down the line.

Looking good pre market following the news release below, which was issued after the close.

DALLAS, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI; MDAIW) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in clinical wound care, today announced that it will participate in the Benchmark 12th Annual Discovery One-on-One Conference being held on December 7, 2023 in New York City.

Management will participate in 1x1 meetings throughout the day with institutional investors. For more information on the Benchmark 12th Annual Discovery One-on-One Conference, or to schedule a one-on-one meeting, please contact your Benchmark representative or visit the Conference Website

I am with interactive investor and my shares haven't landed yet.

The good news keeps flowing, but the share price continues to drop. The ambition here is big and given the appointment and his worldwide knowledge you have to believe this is going to grow rapidly at some point.

DALLAS, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI)

(“Spectral AI” or the “Company”), an artificial intelligence (AI)

company focused on medical diagnostics for faster and more accurate treatment

decisions in wound care, today announced the appointment of Prof. Paul

Chadwick as Executive Vice President of the Company’s United Kingdom

subsidiary. Prof. Chadwick is an experienced clinical scientist and wound care

key opinion leader (KOL) with an impressive body of work including a

substantial and impactful publication record, particularly in the domain of

diabetic wound management. He will be responsible for the international market

expansion of the Company’s DeepView(®) wound imaging technology in the

United Kingdom, Europe, Middle East and Africa (EMEA), all of which are

geographic areas where Prof. Chadwick has extensive clinical networks,

significant experience and has enjoyed previous successes.

“Paul brings over fifteen years of invaluable expertise in the medical

devices and technology sectors to our team. The Royal College of Podiatry is

an extremely prestigious and important organization where Paul most recently

served for over six years in senior executive capacities, including CEO. We

are highly confident that his addition will significantly enhance our efforts

in advancing the widespread adoption of the DeepView(®) System,” said Niko

Pagoulatos, the Company’s COO. “Spectral AI continues to strengthen its

leadership team and Paul’s experience in diabetic foot ulcers and clinical

wound management will contribute to our growth and enhance our capacity to

innovate.”

Prof. Chadwick’s impressive journey stretches across clinical, academic and

business disciplines. In his previous roles at the Royal College of Podiatry,

Prof. Chadwick led all the clinical, educational and financial aspects of the

organization. In addition, he has held multiple leadership positions such as

consultant podiatrist at The National Health Service (NHS), and Managing

Director at Curativo Wound Care Consultancy, where he has served companies

such as 3M, Molnlycke Health Care, Smith & Nephew, Advancis, Thornton & Ross,

Essity and many others. In his capacity as a prominent authority in wound

care, Prof. Chadwick fulfills critical roles on advisory boards and

exemplifies best practices in the field. Furthermore, he generously imparts

his knowledge as an adjunct professor at Birmingham City University, where he

teaches in the Health and Life Sciences Department.

No. Rang up ii last week and they said there had been a problem at their end but this had now been resolved and the shares should be with me early this week, but still nothing.

MDAI have just delivered the following guidance

Financial Guidance

* Research & Development Revenue (“Revenue”) for FY2023 is expected to

approximate $17.4 million

* Revenue for FY2024 is expected to approximate $28.0 million

“We are on the cusp of delivering a distinct, cutting-edge AI-driven wound

healing assessment platform with the potential to significantly improve the

current standard of care across multiple indications,” said Wensheng Fan,

CEO of Spectral AI. “As we continue to advance our burn indication, we are

as excited about the prospects for the use of DeepView(®) for DFU, an

estimated $11.0 billion market that we believe is in dire need of a solution

that provides clinicians with an immediate healing assessment for more

accurate and timely diagnosis and therapeutic intervention. We intend to

submit applications for FDA, UKCA, and CE mark approval for the DeepView(®)

DFU indication, as well as for 3D wound measurement capabilities, in FY2024

subject to the completion of ongoing studies.”

The Company noted that the financial guidance for FY2024 does not reflect the

material financial contributions it expects would result from the

commercialization of DeepView(®) for DFU and 3D wound measurement following

the receipt of necessary regulatory clearances. As previously disclosed, the

Company has received regulatory approval for the DeepView SnapShot(®) device

and the Company will now seek the approval of its integrated AI application to

obtain both UKCA and FDA approval for the commercialization of the complete

DeepView SnapShot(®) System in the United States and across the globe.

“We believe we are in the best position in our history to deliver

significant value for patients dealing with acute and chronic wound

conditions, physicians and health systems that are challenged with effectively

and cost-efficiently managing these conditions, and, of course, our

shareholders,” Mr. Fan concluded.

apologies. missed out numbers. They should have given a steer.

They should have included some otherwise it's just guess work.